PE20071095A1 - Derivados policiclicos de indazol como inhibidores de erk - Google Patents
Derivados policiclicos de indazol como inhibidores de erkInfo
- Publication number
- PE20071095A1 PE20071095A1 PE2006001592A PE2006001592A PE20071095A1 PE 20071095 A1 PE20071095 A1 PE 20071095A1 PE 2006001592 A PE2006001592 A PE 2006001592A PE 2006001592 A PE2006001592 A PE 2006001592A PE 20071095 A1 PE20071095 A1 PE 20071095A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- indazol
- phenyl
- erk
- inhibitors
- Prior art date
Links
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical class C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- -1 4-FLUOR-PHENYL Chemical class 0.000 abstract 2
- 239000002253 acid Substances 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical group 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
SE REFIERE A DERIVADOS POLICICLICOS DE INDAZOL DE FORMULA (1.0), EN DONDE Y1, Y2, Y3 SON INDEPENDIENTEMENTE -CH=, -N= y -CR9=; Z ES 1 A 3; Q ES a), b) ENTRE OTROS; R1 ES -CN, -NH2,-OR10, R10, C(O)R10, -(C(R30)2)n-NR32-C(O)-R10, ENTRE OTROS; R3, R4, R5, R6 Y R7 SON INDEPENDIENTEMENTE H, ALQUENILO, ALQUILO, ENTRE OTROS; R8 ES H, OH, ALQUILO, ENTRE OTROS; R9 ES HALOGENO, CN, NH2, ENTRE OTROS; R35 ES H O ALQUILO(C1-C6); R36 ES H, ALQUILO O -O-ALQUILO. SON SELECCIONADOS: [3-(4-FLUOR-FENIL)-1H-INDAZOL-5-IL]-AMIDA DE ACIDO 3-AMINO-1-{2-OXO-2-[4-(4-PIRIDIN-2-IL-FENIL)-PIPERAZIN-1-IL]-ETIL}-PIRROLIDIN-3-CARBOXILICO, [3-(4-FLUOR-FENIL)-1H-INDAZOL-5-IL]-AMIDA DE ACIDO 3-FORMILAMINO-1-(2-METIL-4-[4-(5-METIL-PIRIMIDIN-2-IL)-FENIL]-PIPERAZIN-1-IL}-2-OXO-ETIL)-PIRROLIDIN-3-CARBOXILICO, ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. ESTOS COMPUESTOS SON INHIBIDORES DE ERK, POR LO QUE SON UTILES EN EL TRATAMIENTO DEL CANCER
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US74985605P | 2005-12-13 | 2005-12-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20071095A1 true PE20071095A1 (es) | 2007-11-19 |
Family
ID=37969564
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2006001592A PE20071095A1 (es) | 2005-12-13 | 2006-12-12 | Derivados policiclicos de indazol como inhibidores de erk |
| PE2010000279A PE20100562A1 (es) | 2005-12-13 | 2006-12-12 | Derivados policiclicos de indazol como inhibidores de erk |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2010000279A PE20100562A1 (es) | 2005-12-13 | 2006-12-12 | Derivados policiclicos de indazol como inhibidores de erk |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US20070191604A1 (es) |
| EP (1) | EP1966151B1 (es) |
| JP (1) | JP4881957B2 (es) |
| KR (1) | KR101417136B1 (es) |
| CN (1) | CN101370784B (es) |
| AR (1) | AR056891A1 (es) |
| AT (1) | ATE527240T1 (es) |
| AU (1) | AU2006326616B2 (es) |
| BR (1) | BRPI0619823B8 (es) |
| CA (1) | CA2633023C (es) |
| CY (1) | CY1112760T1 (es) |
| DK (1) | DK1966151T3 (es) |
| EC (1) | ECSP088550A (es) |
| ES (1) | ES2372976T3 (es) |
| HR (1) | HRP20110892T1 (es) |
| IL (1) | IL192034A (es) |
| MY (1) | MY149430A (es) |
| NO (1) | NO341831B1 (es) |
| NZ (1) | NZ569087A (es) |
| PE (2) | PE20071095A1 (es) |
| PL (1) | PL1966151T3 (es) |
| PT (1) | PT1966151E (es) |
| RS (1) | RS51981B (es) |
| RU (1) | RU2442778C9 (es) |
| SI (1) | SI1966151T1 (es) |
| TW (1) | TWI344466B (es) |
| WO (1) | WO2007070398A1 (es) |
| ZA (1) | ZA200805525B (es) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8546404B2 (en) | 2005-12-13 | 2013-10-01 | Merck Sharp & Dohme | Compounds that are ERK inhibitors |
| KR20080103996A (ko) * | 2006-02-16 | 2008-11-28 | 쉐링 코포레이션 | Ｅｒｋ 억제제로서 피롤리딘 유도체 |
| AU2007269836A1 (en) | 2006-06-30 | 2008-01-10 | Albany Molecular Research, Inc. | Substituted piperidines that increase P53 activity and the uses thereof |
| PE20090326A1 (es) * | 2007-06-05 | 2009-04-04 | Schering Corp | Compuestos heterociclos como inhibidores de erk |
| AR067354A1 (es) | 2007-06-29 | 2009-10-07 | Sunesis Pharmaceuticals Inc | Compuestos utiles como inhibidores de la raf quinasa |
| US20110158944A1 (en) * | 2007-11-30 | 2011-06-30 | Hosted Thomas J | Braf biomarkers |
| CN102015693B (zh) * | 2008-02-21 | 2014-10-29 | 默沙东公司 | 作为erk抑制剂的化合物 |
| EP2265610B1 (en) | 2008-02-29 | 2012-12-12 | Array Biopharma, Inc. | Pyrazole [3, 4-b]pyridine raf inhibitors |
| US20110278332A1 (en) * | 2009-03-26 | 2011-11-17 | Protexer, Inc. | Shoe cover removal apparatus |
| US8637554B2 (en) * | 2008-05-07 | 2014-01-28 | The Trustees Of The University Of Pennsylvania | Methods for treating thyroid cancer |
| US9229008B2 (en) | 2008-08-19 | 2016-01-05 | Merck Sharp & Dohme Corp. | IL-8 level as a determinant of responsivity of a cancer to treatment |
| WO2010021978A2 (en) * | 2008-08-19 | 2010-02-25 | Schering Corporation | Il-8 biomarker |
| EP2448942B1 (en) | 2009-07-02 | 2014-09-24 | Merck Sharp & Dohme Corp. | FUSED TRICYCLIC COMPOUNDS AS mTOR INHIBITORS |
| WO2011041152A1 (en) | 2009-09-30 | 2011-04-07 | Schering Corporation | Novel compounds that are erk inhibitors |
| BR112012008849A2 (pt) | 2009-10-14 | 2015-09-22 | Schering Corp | composto, composição farmacêutica, e, uso de um composto |
| WO2011123937A1 (en) * | 2010-04-06 | 2011-10-13 | University Health Network | Kinase inhibitors and method of treating cancer with same |
| US8999957B2 (en) | 2010-06-24 | 2015-04-07 | Merck Sharp & Dohme Corp. | Heterocyclic compounds as ERK inhibitors |
| EP2608669B1 (en) | 2010-08-23 | 2016-06-22 | Merck Sharp & Dohme Corp. | NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS |
| WO2012030685A2 (en) | 2010-09-01 | 2012-03-08 | Schering Corporation | Indazole derivatives useful as erk inhibitors |
| MX2013006467A (es) | 2010-12-09 | 2013-10-01 | Amgen Inc | Compuestos biciclicos como inhibidores pim. |
| US9351965B2 (en) | 2010-12-21 | 2016-05-31 | Merck Sharp & Dohme Corp. | Indazole derivatives useful as ERK inhibitors |
| EP2688886A1 (en) | 2011-03-22 | 2014-01-29 | Amgen Inc. | Azole compounds as pim inhibitors |
| EP2699567A1 (en) | 2011-04-21 | 2014-02-26 | Merck Sharp & Dohme Corp. | Insulin-like growth factor-1 receptor inhibitors |
| US8901142B2 (en) | 2011-07-26 | 2014-12-02 | Merck Sharp & Dohme Corp. | Fused tricyclic compounds as mTOR inhibitors |
| WO2013062923A1 (en) | 2011-10-28 | 2013-05-02 | Merck Sharp & Dohme Corp. | MACROCYCLES THAT INCREASE p53 ACTIVITY AND THE USES THEREOF |
| WO2013096150A1 (en) | 2011-12-21 | 2013-06-27 | Merck Sharp & Dohme Corp. | Substituted piperidines as hdm2 inhibitors |
| WO2013109142A1 (en) | 2012-01-16 | 2013-07-25 | Stichting Het Nederlands Kanker Instituut | Combined pdk and mapk/erk pathway inhibition in neoplasia |
| ITMI20120135A1 (it) * | 2012-02-02 | 2013-08-03 | Diab Int Ab | Procedimento per la produzione di schiume di pet e schiume di pet ottenute con questo procedimento |
| WO2013169858A1 (en) | 2012-05-08 | 2013-11-14 | The Broad Institute, Inc. | Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy |
| CN103450163B (zh) * | 2012-05-29 | 2017-06-23 | 中国医学科学院药物研究所 | 吲唑类化合物、其制备方法及其药物用途 |
| MX2015003535A (es) | 2012-09-19 | 2015-07-14 | Novartis Ag | Dihidro-pirrolidino-pirimidinas como inhibidoras de cinasa. |
| BR112015006990A2 (pt) * | 2012-09-28 | 2017-07-04 | Merck Sharp & Dohme | composto, composição farmacêutica, e, uso de pelo menos um composto |
| WO2014100065A1 (en) | 2012-12-20 | 2014-06-26 | Merck Sharp & Dohme Corp. | Substituted imidazopyridines as hdm2 inhibitors |
| WO2015041534A1 (en) | 2013-09-20 | 2015-03-26 | Stichting Het Nederlands Kanker Instituut | P90rsk in combination with raf/erk/mek |
| US9629851B2 (en) | 2013-09-20 | 2017-04-25 | Stitching Het Nederlands Kanker Institut—Antoni Van Leeuwenhoek Ziekenhuis | ROCK in combination with MAPK pathway |
| CN105658646B (zh) | 2013-11-01 | 2018-11-27 | 诺华股份有限公司 | 作为激酶抑制剂的氨基杂芳基苯甲酰胺 |
| US20170027940A1 (en) | 2014-04-10 | 2017-02-02 | Stichting Het Nederlands Kanker Instituut | Method for treating cancer |
| WO2015178770A1 (en) | 2014-05-19 | 2015-11-26 | Stichting Het Nederlands Kanker Instituut | Compositions for cancer treatment |
| WO2016095089A1 (en) | 2014-12-15 | 2016-06-23 | Merck Sharp & Dohme Corp. | Erk inhibitors |
| WO2016095088A1 (en) | 2014-12-15 | 2016-06-23 | Merck Sharp & Dohme Corp. | Erk inhibitors |
| US10864179B2 (en) | 2015-10-01 | 2020-12-15 | Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis | Histone deacetylase inhibitors for the use in the treatment of drug resistant melanoma |
| SI3365334T1 (sl) | 2015-10-21 | 2024-10-30 | Otsuka Pharmaceutical Co., Ltd. | Spojine benzolaktama kot zaviralci protein kinaze |
| WO2017099591A1 (en) | 2015-12-07 | 2017-06-15 | Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis | Treatment of inhibitor resistant braf-mutant cancers |
| WO2017156495A1 (en) * | 2016-03-11 | 2017-09-14 | Corvus Pharmaceuticals, Inc. | Compounds and methods for modulating bruton's tyrosine kinase |
| WO2017204626A1 (en) | 2016-05-24 | 2017-11-30 | Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis | Combination therapy - combined map2k4/map3k1 and mek/erk inhibition |
| US10934304B2 (en) * | 2016-10-05 | 2021-03-02 | Recurium Ip Holdings, Llc | Spirocyclic compounds |
| GB201706327D0 (en) | 2017-04-20 | 2017-06-07 | Otsuka Pharma Co Ltd | A pharmaceutical compound |
| WO2019178079A1 (en) | 2018-03-12 | 2019-09-19 | Abbvie Inc. | Inhibitors of tyrosine kinase 2 mediated signaling |
| CN114605329B (zh) * | 2022-03-28 | 2024-01-26 | 河南中医药大学 | 取代的吲唑甲酰胺或取代的氮杂吲唑甲酰胺类flt3抑制剂及其用途 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9213077D0 (en) | 1992-06-19 | 1992-08-05 | Erba Carlo Spa | Polymerbound taxol derivatives |
| SK14082001A3 (sk) * | 2000-02-05 | 2002-03-05 | Vertex Pharmaceuticals Incorporated | Deriváty pyrazolu ako inhibítory ERK a farmaceutická kompozícia, ktorá ich obsahuje |
| US6897231B2 (en) * | 2000-07-31 | 2005-05-24 | Signal Pharmaceuticals, Inc. | Indazole derivatives as JNK inhibitors and compositions and methods related thereto |
| MY130778A (en) * | 2001-02-09 | 2007-07-31 | Vertex Pharma | Heterocyclic inhibitiors of erk2 and uses thereof |
| PL374946A1 (en) * | 2002-09-05 | 2005-11-14 | Aventis Pharma S.A. | Novel aminoindazole derivatives as medicines and pharmaceutical compositions containing same |
-
2006
- 2006-12-11 PL PL06845064T patent/PL1966151T3/pl unknown
- 2006-12-11 HR HR20110892T patent/HRP20110892T1/hr unknown
- 2006-12-11 RS RS20110516A patent/RS51981B/sr unknown
- 2006-12-11 MY MYPI20082076A patent/MY149430A/en unknown
- 2006-12-11 CN CN2006800527776A patent/CN101370784B/zh not_active Expired - Fee Related
- 2006-12-11 BR BRPI0619823A patent/BRPI0619823B8/pt not_active IP Right Cessation
- 2006-12-11 US US11/636,954 patent/US20070191604A1/en not_active Abandoned
- 2006-12-11 PT PT06845064T patent/PT1966151E/pt unknown
- 2006-12-11 CA CA2633023A patent/CA2633023C/en active Active
- 2006-12-11 ES ES06845064T patent/ES2372976T3/es active Active
- 2006-12-11 AU AU2006326616A patent/AU2006326616B2/en not_active Ceased
- 2006-12-11 SI SI200631221T patent/SI1966151T1/sl unknown
- 2006-12-11 KR KR1020087016729A patent/KR101417136B1/ko not_active Expired - Fee Related
- 2006-12-11 DK DK06845064.2T patent/DK1966151T3/da active
- 2006-12-11 RU RU2008128119/04A patent/RU2442778C9/ru active
- 2006-12-11 WO PCT/US2006/046959 patent/WO2007070398A1/en not_active Ceased
- 2006-12-11 NZ NZ569087A patent/NZ569087A/en not_active IP Right Cessation
- 2006-12-11 JP JP2008545685A patent/JP4881957B2/ja not_active Expired - Fee Related
- 2006-12-11 EP EP06845064A patent/EP1966151B1/en active Active
- 2006-12-11 AT AT06845064T patent/ATE527240T1/de active
- 2006-12-12 TW TW095146375A patent/TWI344466B/zh not_active IP Right Cessation
- 2006-12-12 AR ARP060105474A patent/AR056891A1/es active IP Right Grant
- 2006-12-12 PE PE2006001592A patent/PE20071095A1/es active IP Right Grant
- 2006-12-12 PE PE2010000279A patent/PE20100562A1/es not_active Application Discontinuation
-
2008
- 2008-06-10 IL IL192034A patent/IL192034A/en active IP Right Grant
- 2008-06-13 EC EC2008008550A patent/ECSP088550A/es unknown
- 2008-06-24 ZA ZA200805525A patent/ZA200805525B/xx unknown
- 2008-07-11 NO NO20083114A patent/NO341831B1/no not_active IP Right Cessation
-
2012
- 2012-01-04 CY CY20121100006T patent/CY1112760T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20071095A1 (es) | Derivados policiclicos de indazol como inhibidores de erk | |
| NO20063470L (no) | Tetrazolforbindelser og deres anvendelse av metabotrofe glutamatreseptorantagonister | |
| NO20090328L (no) | Nye forbindelser 385 | |
| EA200900658A1 (ru) | Производные индазолилэфиров или -амидов для лечения расстройств, опосредованных глюкокортиодными рецепторами | |
| PE20090326A1 (es) | Compuestos heterociclos como inhibidores de erk | |
| NO20074275L (no) | 2- (4-okso-4H-kinazolin-3-yl) acetamider og deres anvendelse som Vasopressin-V3-antagonister | |
| TW200745111A (en) | New compounds | |
| MY146662A (en) | Novel n-(8-heteroaryltetrahydronaphtalene-2yl) or n-(5-heteroarylchromane-3-yl) carboxamide derivatives for the treatment of pain | |
| PE20091734A1 (es) | Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso | |
| PE20121352A1 (es) | Derivados de heteroarilo que contienen n como inhibidores de cinasa jak3 | |
| NO20063469L (no) | Polyeheterosykliske forbindelser og deres anvendelse som metabotrofe glutamat reseptorantagonister | |
| PE20091561A1 (es) | Compuestos inhibidores de raf y metodos para su uso | |
| PE20060857A1 (es) | Derivados de piridinilo y pirimidinilo sustituidos como moduladores del metabolismo y para tratar trastornos metabolicos | |
| NO20090760L (no) | Nye tricykliske spiropiperidinforbindelser, deres synteser og deres anvendelser som modulatorer av kemokinreseptor-aktivitet | |
| PE20140609A1 (es) | Diazacarbazoles y metodos de uso | |
| PE20090816A1 (es) | Derivados de pirrolopirimidinona como agentes ligandos de los receptores p2x3 | |
| NO20083909L (no) | Bisykliske benzimidazolforbindelser, og deres anvendelse som metabotropiske glutamatreseptorforsterkere | |
| PE20091623A1 (es) | DERIVADOS DE 1H-PIRAZOLO[3,4-b]PIRIDINA COMO INHIBIDORES DE RAF QUINASA | |
| MX2010009022A (es) | Derivados 16 alfa, 17 alfa-acetal glucocorticoesteroideos y su uso. | |
| NO20084418L (no) | Azolopyridin-3-on derivater som inhibitorer av endoteliallipase | |
| PE20081393A1 (es) | Derivados de quinolina como inhibidores de csf-1r | |
| NO20082496L (no) | Pyrazinderivater | |
| MY162022A (en) | Chemical compounds 637: pyridopyrimidinediones as pde4 inhibitors | |
| ATE364044T1 (de) | 5ht2c rezeptor agonisten zur behandlung von diabetes und fettleibigkeit | |
| SE0403171D0 (sv) | New compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |